BERKLEY W R CORP

BERKLEY W R CORP (WRB) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Why is the moat durable and why does it compound?
  It doesn’t compound in a wide, self‑reinforcing way. The moat is operational discipline — underwriting rigor and float management that consistently produce ROE above cost of capital (18.3% in 2025 vs. ~10% hurdle). Niche excess‑lines relationships create moderate switching costs; brokers and clients stick with Berkley because re‑quoting is a pain and the underwriting is reliable. That reliability, not technology or brand, gives them pricing power during hard markets.

• What makes the economics exceptional — specifically?
  Float. Berkley collects $14.7B in premiums upfront and invests in bonds/stocks. Net investment income cushions underwriting results, turning the insurance cycle from a liability into an asset. Revenue grew 91% from $7.7B (2016) to $14.7B (2025) — rate‑led, not volume‑driven. Net income CAGR of 13.5% and ROE peaking at 20.9% (2024) prove they can raise prices when the market allows. Marginal returns on incremental capital are decent because they don’t need heavy reinvestment — just smarter pricing.

• At what price range does this become genuinely attractive to Berkshire?
  Only at a deep discount to book value, reflecting the cyclical risk and hidden leverage. If WRB traded at ~1.0x book (roughly $50–$55 per share), the downside from a soft cycle would be partially priced in, and the float would provide a cushion. At that level, Berkshire could buy a disciplined underwriter with a long‑term track record — but only if management opened the books on FCF and debt.

🐻 The Bear Case (Charlie inverts)

• 2–3 scenarios that permanently impair this business:

  1. The “Lost Decade” of soft pricing + catastrophe. A prolonged soft market (rates falling for 5+ years) combined with a mega‑catastrophe (e.g., $10B+ industry loss) that exhausts reserves. Berkley’s float becomes a liability — suddenly they must pay claims while investment income shrinks. No moat protects against industry‑wide underpricing.
  2. Tech disintermediation of excess lines. A data‑driven platform (e.g., an AI‑powered broker) that erodes Berkley’s niche underwriting edge. If algorithms can price excess liability better than human underwriters, switching costs vanish. WRB becomes a commodity carrier trapped in a downward pricing spiral.
  3. Hidden leverage + rising loss costs. Debt not disclosed in your data; interest coverage unknown. If reserves are inadequate (common in P&C) and investment losses mount, WRB could be forced to raise capital at dilutive terms. The 4.0% ROA reveals thin earnings power — leverage juicing ROE is fragile.

• Which is most likely, and over what timeframe?
  Scenario #1 is the most probable within a 5–10 year window. Insurance cycles are inevitable; Berkley has navigated them well, but the missing FCF from 2020 onward suggests cash generation has deteriorated. A single bad cycle could permanently impair capital.

💰 Valuation & Margin of Safety

• DCF estimate (from your analysis): $90.62 per share (7.4% FCF growth, 10% discount rate, 3% terminal growth).
• 25% margin of safety entry: $67.97 (conservative)
• 50% margin of safety entry: $45.31 (Buffett's ideal — only if the moat is truly durable; here, it’s not)
• Current price vs. intrinsic value: No current price provided. Based solely on the DCF, WRB appears fairly valued if it trades near $90. But given the red flags (missing FCF, hidden debt, 4% ROA), a fair price should be at least 30‑40% below DCF to account for cyclical and structural risks. Without knowing the market price, we cannot determine if it’s cheap or expensive — only that the margin of safety required is large.

Verdict: PASS

The intrinsic value is $90.62 per share, but the moat is cyclical and thin — the missing free cash flow, undisclosed debt, and 4% return on assets are dealbreakers for permanent capital. We will not buy unless WRB trades below $50 per share and management fully transparently discloses cash flows and leverage — and even then, the insurance treadmill offers no compounding magic.